https://www.selleckchem.com/pr....oducts/SB-431542.htm
Myrcludex B and Lonafarnib increase therapeutic efficacy in combination with Peg-IFN alfa. In a pilot study, REP 2139 in combination with Peg-IFN alfa induced the clearance of serum HDV RNA and of the HBsAg in about half of 12 treated patients. IMPLICATIONS Long-term therapies with either Myrcludex B or Lonafarnib in combination with Peg-IFN alfa are required to achieve clinical control of CHD. However, with prolonged therapies tolerance becomes a problem; studies are on the way to determine whether Peg-IFN lambda may be better tolera
Like
Comment
Share
